Homocysteine: Call off the funeral

Stroke

Volumn 37, Issue 2, 2006, Pages 282-283

  Spence, J David ^a  

^a Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

Hyperhomocysteinemia

Indexed keywords

BETAINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; THIOL DERIVATIVE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AGING; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; EDITORIAL; HUMAN; PRIORITY JOURNAL; RISK REDUCTION; VITAMIN SUPPLEMENTATION; BLOOD; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; GENETIC POLYMORPHISM; GENETICS; HYPERHOMOCYSTEINEMIA; METABOLISM; NOTE;

CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; VITAMIN B 12;

EID: 33644855617     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000199621.28234.e2     Document Type: Editorial

References (21)

1. Bønaa KH. NORVIT: randomised trial of homocysteine-lowering with B vitamins for secondary prevention of cardiovascular disease after acute myocardial infarction. Stockholm. Sept 5, 2005. European Society of Cardiology. http://www.escardio.org/knowledge/onlinelearning/slides/ESC_Congress_2005/ BonaaFP1334.htm. Accessed November 24, 2005.
2. Davey Smith G, Ebrahim S. Folate supplementation and cardiovascular disease. Lancet. 2005;366:1679-1681.
3. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Stampfer M, Wang C-H. Lowering plasma total homocysteine to prevent recurrent stroke, myocardial infarction, and death in ischemic stroke patients: results of the Vitamin Intervention for Stroke Prevention (VISP) Randomized Trial. J Am Med Assoc. 2004;291:565-575.
4. The VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis. 2004;13:120-126.
5. Ho GY-H, Eikelboom JW, Hankey GJ, Wong C-R, Tan S-L, Chen CP-H. Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. Stroke. 2006;37:456-460.
6. Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, Yi Q, Klijn CJ, Langton P, van Bockxmeer FM, Baker R, Jamrozik K. Homocysteine- lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke. 2005;36:144-146.
7. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology. 2001;20:16-25.
8. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc. 2002;50:1789-1795.
9. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke;36:2404-2409.
10. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol. 1999;18:405-410.
11. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
12. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. J Am Med Assoc. 2002;288:973-979.
13. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681.
14. Andres E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, Noblet-Dick M, Maloisel F, Schlienger JL, Blickle JF. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004;171:251-259.
15. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60:2-11.
16. Johnston CS, Thomas JA. Holotranscobalamin II levels in plasma are related to dementia in older people. J Am Geriatr Soc. 1997;45:779-780.
17. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. Increased importance of Vitamin B12 for total homocysteine and carotid plaque in the era of folate fortification of the grain supply. CMAJ. 2005;172:1569-1573.
18. Quinlivan EP, McPartlin J, McNulty H, Ward M, Strain JJ, Weir DG, Scott JM. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet. 2002;359:227-228.
19. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003;133:4135-4138.
20. House AA, Eliasziw M, Urquhart BL, Freeman DJ, Spence JD. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. Am J Kidney Dis. 2004;44:689-694.
21. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetyl-cysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004;109:369-374.